A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects with Major Depressive Disorder. Save

Date Added
January 22nd, 2019
PRO Number
Pro00084417
Researcher
Robert Malcolm

List of Studies


Profiles_link
Keywords
Depression
Summary

The purpose of this study is to determine if taking JNJ-67953964 (the investigational medication), in addition to a currently prescribed anti-depressant, is useful and safe for treating patients with Major Depressive Disorder. This will be compared to placebo plus subjects' current anti-depressant medication.

Institution
MUSC
Recruitment Contact
Melissa Michel
843-792-1901
michelm@musc.edu

Change_preferences

-- OR --

Create_login